DE602004007895D1 - Diagnostisches verfahren zur vorhersage von nierentransplantations-abstossung - Google Patents

Diagnostisches verfahren zur vorhersage von nierentransplantations-abstossung

Info

Publication number
DE602004007895D1
DE602004007895D1 DE602004007895T DE602004007895T DE602004007895D1 DE 602004007895 D1 DE602004007895 D1 DE 602004007895D1 DE 602004007895 T DE602004007895 T DE 602004007895T DE 602004007895 T DE602004007895 T DE 602004007895T DE 602004007895 D1 DE602004007895 D1 DE 602004007895D1
Authority
DE
Germany
Prior art keywords
renewal
dispersion
diagnostic procedure
predicting lung
predicting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004007895T
Other languages
English (en)
Other versions
DE602004007895T2 (de
Inventor
Andrea Galli
Paola Romagnani
Mario Serio
Calogero Surrenti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regione Toscana Florenz/firenze It
Universita degli Studi di Firenze
Original Assignee
Universita degli Studi di Firenze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita degli Studi di Firenze filed Critical Universita degli Studi di Firenze
Publication of DE602004007895D1 publication Critical patent/DE602004007895D1/de
Application granted granted Critical
Publication of DE602004007895T2 publication Critical patent/DE602004007895T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
DE602004007895T 2003-03-06 2004-03-02 Diagnostisches verfahren zur vorhersage von nierentransplantations-abstossung Expired - Lifetime DE602004007895T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000058A ITFI20030058A1 (it) 2003-03-06 2003-03-06 Formulazioni farmaceutiche contenenti tiazolidinedioni
ITFI20030058 2003-03-06
PCT/EP2004/002069 WO2004078175A2 (en) 2003-03-06 2004-03-02 Pharmaceutical preparations containing thiazolidinediones for the treatment or prevention of ip-10 mediated diseases

Publications (2)

Publication Number Publication Date
DE602004007895D1 true DE602004007895D1 (de) 2007-09-13
DE602004007895T2 DE602004007895T2 (de) 2008-04-17

Family

ID=32948189

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004007895T Expired - Lifetime DE602004007895T2 (de) 2003-03-06 2004-03-02 Diagnostisches verfahren zur vorhersage von nierentransplantations-abstossung

Country Status (14)

Country Link
US (1) US20060287372A1 (de)
EP (2) EP1830191A3 (de)
JP (1) JP2006519799A (de)
AT (1) ATE368859T1 (de)
AU (1) AU2004216823B2 (de)
CA (1) CA2518199A1 (de)
CY (1) CY1108098T1 (de)
DE (1) DE602004007895T2 (de)
DK (1) DK1601355T3 (de)
ES (1) ES2290678T3 (de)
IT (1) ITFI20030058A1 (de)
PL (1) PL1601355T3 (de)
PT (1) PT1601355E (de)
WO (1) WO2004078175A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
ITFI20040243A1 (it) * 2004-11-25 2005-02-25 Paola Romagnani Metodo diagnostico per la previsione di rigetto di organo trapiantato
GB0504206D0 (en) * 2005-03-01 2005-04-06 Glaxo Group Ltd Combination therapy
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
ES2388555T3 (es) 2006-03-16 2012-10-16 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
EP2205565B1 (de) 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituierte 4-(phenyl)-1h-pyridin-2-one
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
NZ584145A (en) 2007-09-14 2012-03-30 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
MX2010005110A (es) 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (de) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinationen mit positiven allosterischen modulatoren von metabotropem glutamatergen rezeptor vom subtyp 2 und deren verwendung
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
EP3568134A1 (de) * 2017-01-16 2019-11-20 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur reduzierung der cd95-vermittelten zellmotilität

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE210663T1 (de) * 1994-06-20 2001-12-15 Takeda Chemical Industries Ltd Kondensierte imidazolderivate, ihre herstellung und verwendung
WO1997045141A1 (fr) * 1996-05-31 1997-12-04 Sankyo Company, Limited Remede pour maladies auto-immunes
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
CA2350599A1 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US6369098B1 (en) * 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US6703202B2 (en) * 1999-11-30 2004-03-09 Oxo Chemie Ag Evaluating and predicting clinical outcomes by gene expression analysis
WO2001062238A2 (en) * 2000-02-24 2001-08-30 San Diego State University Ppar gamma agonists for the treatment of liver inflammatory disorders
US20020019344A1 (en) * 2000-02-26 2002-02-14 Pershadsingh Harrihar A. Methods of preventing allograft rejection
US20020018776A1 (en) * 2000-04-14 2002-02-14 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CXCR3 function
FR2823225B1 (fr) * 2001-04-04 2004-09-17 Pierre Desreumaux Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant
US7244555B2 (en) * 2002-05-14 2007-07-17 Renovak Inc Systems and methods for identifying organ transplant risk

Also Published As

Publication number Publication date
CA2518199A1 (en) 2004-09-16
AU2004216823B2 (en) 2009-07-16
DE602004007895T2 (de) 2008-04-17
WO2004078175A2 (en) 2004-09-16
AU2004216823A1 (en) 2004-09-16
EP1830191A3 (de) 2007-10-03
CY1108098T1 (el) 2014-02-12
PL1601355T3 (pl) 2007-12-31
EP1601355B1 (de) 2007-08-01
ES2290678T3 (es) 2008-02-16
JP2006519799A (ja) 2006-08-31
EP1601355A2 (de) 2005-12-07
DK1601355T3 (da) 2007-12-17
PT1601355E (pt) 2007-11-15
WO2004078175A3 (en) 2004-12-09
US20060287372A1 (en) 2006-12-21
ITFI20030058A1 (it) 2004-09-07
ATE368859T1 (de) 2007-08-15
EP1830191A2 (de) 2007-09-05

Similar Documents

Publication Publication Date Title
DE602004007895D1 (de) Diagnostisches verfahren zur vorhersage von nierentransplantations-abstossung
DE60128916D1 (de) Neues, physiologisch aktives peptid und dessen verwendung
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
DE602004031771D1 (de) Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
DK2000545T3 (da) Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
ATE536855T1 (de) Gewebegerüste zusamensetzungen zur behandlung von zahnerkrankungen
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
WO2005012530A3 (en) Antagonists and agonists of ldcam and methods of use
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
CY1110316T1 (el) Χρηση πιπαμπερονης και ενος sndri, snri ή ssri για την θεραπεια διαταραχων ψυχικης διαθεσης ή αγχους
DK2157192T3 (da) Sammensætninger til diagnose og terapi af sygdomme forbundet med afvigende ekspression af futriner (R-spondiner)
SE0301446D0 (sv) New Compounds
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
ATE527377T1 (de) Erstellung von genexpressionprofilen aus ffpe- proben
WO2007030708A3 (en) Antimicrobial adzymes and uses thereof
DE60207612D1 (de) Verbindungen zur bilddarstellung der alzheimer-krankenheit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: UNIVERSITA DEGLI STUDI DI FIRENZE, FLORENZ/FIR, IT

Owner name: REGIONE TOSCANA, FLORENZ/FIRENZE, IT